PeptiCRAd-1

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NamePeptiCRAd-1
Drug Alias NameValo-D102PeptiCRAd-1
ClassificationVaccines > Application > Therapeutic vaccineCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionCell death stimulantsImmunostimulantsTumor necrosis factor receptor superfamily member 4 agonists +[5] 
TargetsTumor necrosis factor receptor superfamily member 4Tumor necrosis factor receptor superfamily member 5Cancer/testis antigen 1
Therapy Area/IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesValor Biotherapeutics
China Registration ClassN/A

Develop Information

Active CompaniesValo Therapeutics OyValor Biotherapeutics
Inactive CompaniesN/A
Active IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A